Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

INTRODUCTION: Predictive cancer biomarkers to guide the right treatment to the right patient at the right time are strongly needed. The purpose of the present study was to validate prior results that tissue inhibitor of metalloproteinase 1 (TIMP-1) alone or in combination with either HER2 or TOP2A c...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Munro, Alison F, Bartels, Annette, Balslev, Eva, Twelves, Christopher J, Cameron, David A, Brünner, Nils, Bartlett, John MS
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2013
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3672718/
https://ncbi.nlm.nih.gov/pubmed/23570501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3411
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים